We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+6.14%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.52B
AUM Growth
+$385M
Cap. Flow
+$3.2M
Cap. Flow %
0.04%
Top 10 Hldgs %
34.42%
Holding
155
New
17
Increased
44
Reduced
30
Closed
23

Top Buys

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$102M
2
CFN
CAREFUSION CORPORATION
CFN
+$68.7M
3
BMY icon
Bristol-Myers Squibb
BMY
+$60.2M
4
SHPG
Shire pic
SHPG
+$55.3M
5
TRNX
TORNIER N V SHARES (NLD)
TRNX
+$54M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$146M
2
AGN
Allergan Inc
AGN
+$113M
3
PRTA icon
Prothena Corp
PRTA
+$72.4M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$63M
5
XLRN
Acceleron Pharma
XLRN
+$56.7M

Sector Composition

Rank Sector Weight
1 Healthcare 82.59%
2 Financials 0.08%
3 Technology 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ICPT
1
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$391M 4.59%
1,656,258
-78,676
-5% -$20.7M
BMY icon
2
Bristol-Myers Squibb
BMY
$130B
$349M 4.09%
7,189,000
+1,222,600
+20% +$60.2M
BIIB icon
3
Biogen
BIIB
$32.1B
$342M 4.01%
1,084,200
+23,500
+2% +$7.07M
ABBV icon
4
AbbVie
ABBV
$471B
$294M 3.45%
5,204,200
+410,400
+9% +$21.5M
GILD icon
5
Gilead Sciences
GILD
$166B
$285M 3.34%
3,434,800
-1,880,000
-35% -$146M
AMGN icon
6
Amgen
AMGN
$212B
$266M 3.12%
2,245,000
-70,900
-3% -$8.21M
AGN
7
DELISTED
Allergan Inc
AGN
$261M 3.07%
1,543,700
-726,300
-32% -$113M
HCA icon
8
HCA Healthcare
HCA
$90.7B
$254M 2.99%
4,513,000
+298,000
+7% +$15.7M
ILMN icon
9
Illumina
ILMN
$29.3B
$247M 2.91%
1,424,808
+26,214
+2% +$3.91M
RLYP
10
DELISTED
RELYPSA INC COM
RLYP
$242M 2.84%
9,941,551
– –
ITMN
11
DELISTED
INTERMUNE INC
ITMN
$240M 2.81%
5,425,200
-526,800
-9% -$19.4M
CELG
12
DELISTED
Celgene Corp
CELG
$228M 2.68%
2,655,000
-87,800
-3% -$6.68M
SHPG
13
DELISTED
Shire pic
SHPG
$213M 2.5%
905,200
+318,200
+54% +$55.3M
VTRS icon
14
Viatris
VTRS
$20.8B
$204M 2.39%
3,952,700
+47,200
+1% +$2.32M
INCY icon
15
Incyte
INCY
$25.3B
$198M 2.32%
3,500,400
+376,400
+12% +$19.2M
MDVN
16
DELISTED
MEDIVATION, INC.
MDVN
$189M 2.21%
4,893,200
-555,000
-10% -$18.7M
TMO icon
17
Thermo Fisher Scientific
TMO
$215B
$181M 2.13%
1,535,700
+142,500
+10% +$16.8M
A icon
18
Agilent Technologies
A
$39.6B
$180M 2.11%
4,376,159
+122,604
+3% +$4.92M
PRGO icon
19
Perrigo
PRGO
$1.44B
$172M 2.02%
1,181,700
+124,900
+12% +$17.7M
CFN
20
DELISTED
CAREFUSION CORPORATION
CFN
$163M 1.91%
3,671,000
+1,659,000
+82% +$68.7M
IPXL
21
DELISTED
Impax Laboratories, Inc.
IPXL
$162M 1.91%
5,415,600
+70,000
+1% +$1.89M
ISRG icon
22
Intuitive Surgical
ISRG
$128B
$161M 1.89%
3,519,900
+493,200
+16% +$21.8M
MRK icon
23
Merck
MRK
$325B
$147M 1.72%
2,659,824
-9,432
-0.4% -$515K
ESRX
24
DELISTED
Express Scripts Holding Company
ESRX
$144M 1.69%
2,079,000
-18,000
-0.9% -$1.27M
IRWD icon
25
Ironwood Pharmaceuticals
IRWD
$602M
$137M 1.61%
10,669,465
+9,377,438
+726% +$102M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2014 Portfolio in Review

As of Q2 2014, OrbiMed held 155 positions worth $8.52B, up 4.7% from $8.13B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed's Q2 2014 filing shows 17 new, 44 increased, 30 reduced and 23 closed positions. Its largest new stake was Alkermes: 433,300 shares worth $21.8M. The largest sale was Gilead Sciences, an estimated $146M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 83% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q2 2014 buy was Alkermes: 433,300 shares worth $21.8M.
  • OrbiMed added most to Ironwood Pharmaceuticals in Q2 2014, an estimated $102M increase.
  • OrbiMed's biggest Q2 2014 reduction was Gilead Sciences, cutting an estimated $146M.
  • OrbiMed fully exited Prothena Corp in Q2 2014, selling an estimated $72.4M.
  • OrbiMed's ten largest holdings make up 34% of its $8.52B portfolio in Q2 2014.
  • OrbiMed opened 17 new positions and closed 23 in Q2 2014.
  • OrbiMed's portfolio value rose 4.7% quarter-over-quarter to $8.52B.

Based on OrbiMed's 13F filing for Q2 2014, filed 14 Aug 2014.